Granules India gets licence from DRDO to manufacture and market COVID-19 drug 2-DG

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients
Read Article

Granules India yesterday said it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

“Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.

The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.

anti-COVID drug 2-DGCOVID-19 drugDCGIDRDOGranules India
Comments (0)
Add Comment